文献詳細
特集 古くて新しい前立腺炎の臨床
文献概要
要旨 NIH category Ⅲを生じる原因の1つとして,排尿障害による尿の前立腺導管内への逆流がある。α1-blockerは前立腺および尿道内の抵抗を低下させて前立腺組織への尿の逆流を防止するとされ,NIH category Ⅲの治療薬の1つとなっている。これまで報告されたα1-blockerのNIH category Ⅲに対する効果はまちまちであるが,meta-analysisでは有効性が証明されている。したがってNIH category Ⅲに対しα1-blockerは有効性が期待されるが,経過が長い症例などでは効果が期待できない場合もある。今後も引き続き検討が望まれるが,まずは評価法の統一などを行う必要がある。
参考文献
1)Executive summary:NIH workshop on chronic prostatitis. Bethesda, Maryland, 1995
2)Gül O, Eroğlu M and Ozok U:Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Int Urol Nephrol 32:433-436, 2001
3)Evliyaoğlu Y and Burgut R:Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin;versus placebo. Int Urol Nephrol 34:351-356, 2002
4)Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al:The National Institutes of Health chronic prostatitis symptom index:development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 162:369-375, 1999
5)Cheah PY, Liong ML, Yuen KH, et al:Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome:a randomized, placebo controlled trial. J Urol 169:592-596, 2003
6)Mehik A, Alas P, Nickel JC, et al:Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome:a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology 62:425-429, 2003
7)Nickel JC, Krieger JN, McNaughton-Collins M, et al:Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 359:2663-2673, 2008
8)Nickel JC, Narayan P, McKay J, et al:Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin:a randomized double blind trial. J Urol 171:1594-1597, 2004
9)Ye ZQ, Lan RZ, Yang WM, et al:Tamsulosin treatment of chronic non-bacterial prostatitis. J Int Med Res 36:244-252, 2008
10)Alexander RB, Propert KJ and Schaeffer AJ:Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome:a randomized, double-blind trial. Ann Intern Med 141:581-589, 2004
11)Tuğcu V, Taşçi AI, Fazlioğlu A, et al:A placebo-controlled comparison of the efficiency of triple-and monotherapy in category Ⅲ B chronic pelvic pain syndrome(CPPS). Eur Urol 51:1113-1117, 2007
12)Jeong CW, Lim DJ, Son H, et al:Treatment for chronic prostatitis/chronic pelvic pain syndrome:levofloxacin, doxazosin and their combination. Urol Int 80:157-161, 2008
13)Nickel JC, O'Leary MP, Lepor H, et al:Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome:results of a phase Ⅱ multicenter, double-blind, placebo controlled study. J Urol 186:125-131, 2011
アドレナリン受容体遮断薬ナフトピジルによる臨床的有効性の検討―日本語版NIH-CPSIを用いた投与前後4週間の比較.泌尿器科紀要56:215-219,2010
15)門田晃一,津川昌也,二ノ宮裕子,他:The National Institutes of Health chronic prostatitis symptom index(NIH-CPSI,日本語版・岡山大学案)の有用性と同案を用いた慢性非細菌性前立腺炎に対するセルニチンポーレンエキスの臨床評価.日泌尿会誌93:539-547,2002
16)Anothaisintawee T, Attia J, Nickel JC, et al:Management of chronic prostatitis/chronic pelvic pain syndrome:a systematic review and network meta-analysis. JAMA 305:78-86, 2011
17)Thakkinstian A, Attia J, Anothaisintawee T, et al:α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2012 Apr 3.[Epub ahead of print]
掲載誌情報